Integer's CRM Division Head Eased Out Amid Active Sale Process
Strategic Review
Company Background
Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations in the world, serving the cardiac rhythm management, neuromodulation, and cardio & vascular markets under its Greatbatch Medical and Lake Region Medical brands. The company reported full-year 2025 sales of $1.85 billion, with adjusted EPS growing 21%, before a marked slowdown: first-quarter 2026 adjusted operating income fell 14% and adjusted EPS dropped 8% year-over-year as new-product headwinds bit. Net total debt stood at $1.26 billion as of April 3, 2026, at a leverage ratio of 3.2 times adjusted EBITDA.
The governance picture has shifted sharply since early 2026. Irenic Capital Management secured a cooperation agreement on March 9, 2026, placing two directors — James Flanagan and Aaron Kapito — on the board and causing two incumbent directors to stand down. On April 30, 2026, alongside first-quarter results, the board announced a formal strategic review "to maximize stockholder value," explicitly considering a sale, merger, or strategic business combination. Goldman Sachs is acting as financial adviser. There is no stated deadline for the review.
What Was Disclosed
Jim Stephens, Integer's President of Cardiac Rhythm Management & Neuromodulation, has been moved to a newly created role of Executive Vice President, Special Projects, effective June 29, 2026. The compensation changes were approved by the Compensation and Organization Committee on June 24, 2026, and formalized in a letter agreement dated June 26, 2026. No successor to Stephens in the CRM & Neuromodulation president role was named.
The letter agreement sets a fixed termination date of March 31, 2027 for the Special Projects role, unless either party ends it earlier. Stephens will not be eligible for short-term or long-term incentive awards in 2027. Critically, the agreement contains explicit change-of-control language: if a change of control occurs on or before March 31, 2027, and Stephens remains employed through that date, his separation will be treated as a termination without cause under his Amended and Restated Change of Control Agreement dated May 22, 2026 — entitling him to the associated severance benefits.
All other terms of his employment remain unchanged. The filing was made under Item 5.02, covering compensation arrangements of certain officers.
Why It Matters
Cardiac Rhythm Management & Neuromodulation is one of Integer's two core product lines, generating $668.8 million in full-year 2025 sales — roughly 36% of total company revenue. The segment posted 4.9% organic growth in the first quarter of 2026, making it Integer's better-performing division at the moment. Removing the segment president without naming a replacement introduces a leadership gap at a unit that would likely be central to any strategic transaction.
The timing and structure of Stephens's exit point in the same direction. On May 20, 2026 — six weeks before this transition — the Compensation Committee awarded Stephens a $451,350 cash retention bonus, structured with 50% payable on December 31, 2026 and 50% vesting only upon a change of control. The letter agreement formalizing his exit now layers on explicit change-of-control protections through March 31, 2027. Taken together, the retention bonus that pays out on a deal and the CIC-protected departure window signal that Integer's internal planning horizon for a potential transaction runs through the first quarter of 2027 at the latest.
The absence of a named successor does create a real operational question. Whether that reflects a deliberate decision to consolidate leadership ahead of a transaction, or simply a gap yet to be filled, is not disclosed. What is clear is that Integer is navigating a board-initiated sale process, a freshly installed activist-aligned board, and a weakening near-term financial profile — all while the leadership of its largest single segment transitions to a holding pattern with a defined end date.
